Effects of the N-type Ca2+ channel blocker, Cilnidipine: Atelec, on blood pressure levels and atherosclerosis indices in hypertensive patients with cerebrovascular disease.

Trial Profile

Effects of the N-type Ca2+ channel blocker, Cilnidipine: Atelec, on blood pressure levels and atherosclerosis indices in hypertensive patients with cerebrovascular disease.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 May 2016

At a glance

  • Drugs Cilnidipine (Primary)
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms CA-ATTEND
  • Sponsors Ajinomoto Pharma
  • Most Recent Events

    • 10 May 2011 Trial status has been changed from not yet recruiting to recruiting as reported University Hospital Medical Information Network - Japan.
    • 29 Apr 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top